Claris Ventures

With a $600M capital commitment for investment, Pfizer Ventures backs private companies at all stages of development. We have a strong focus on early-stage opportunities. But other investments, including start-ups and spinouts, are also considered in scope. While primarily U.S. focused, international investments may represent up to 20 percent of the portfolio. We can lead or join a syndicate of investors and will seek board representation commensurate with our investment. Areas of focus Our investments are focused on potentially transformative therapeutics, with an emphasis in our core therapeutic areas: Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, and Vaccines. We also consider platform technologies, diagnostics, drug delivery, pharmaceutical services, and other technologies that have the potential to transform drug discovery and development Advantages of working with usPfizer Ventures is an active investor, working with management to develop product strategy and shareholder value. We bring a pharmaceutical perspective and have the potential to utilize our internal networks and expertise. We have a streamlined approval process for investment decisions. All investments have the potential for a business relationship with Pfizer.

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!

Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments. It is the first and only U.S. affiliate for Mirae Asset dedicated to investment in Life Science. Near-Term ValueThe majority of our investments will be Series A/B and entering the clinic within a few years to generate real value with clinical proof of concept We believe companies at this stage maximize returns given the risk; we remain open to seed opportunities where there is a clear path to value and Series C opportunities if the valuation and resulting equity ownership support meaningful returns to our investors We aim to find the right mix between first-in-class and best-in-class assets with meaningful market share and evaluate both platform and single asset approaches Calculated RiskWe are modality agnostic when it comes to therapeutics and incredibly opportunistic with diagnostics Our interest in digital health involves using AI/ML tools (e.g. quantum computing, generative biology/chemistry) for drug discovery or protein engineering We co-invest with top-tier life science investors who we know and have worked with before and leverage our operational experience to find strong management teams with excellent track records relevant to the company they are building We aim to be active investors by securing board roles whenever possible; this is a role that is familiar to us and helps mitigate risk to our investors by helping to shape the course of our investments Innovative yet Validated ModalitiesWe have selected five core therapeutic sectors to focus our investments: Oncology, Immunology, CV/Metabolic, CNS/Ophthalmology, and Rare/Genetic Disease For each of the above sectors we have defined various focus areas defined by a unique combination of validation, unmet need, market potential, and acquisition/public market interest We seek to limit biological and technical risk and prioritize small molecule, antibody approaches (includes mAbs, bsAbs/TCEs, ADCs, radiotherapeutics), and nucleic acid therapeutics (siRNA, ASOs) across these sectors Rigorous EvaluationWe leverage the combined scientific background of our team and our affiliates in Asia (medicinal chemistry, pharmacology, structural biology) to perform rigorous evaluation of each investment We prepare a comprehensive diligence memo for each investment that includes a thorough evaluation of the science, pipeline, finance, management, board, investors, operations, regulatory, IP, clinical development, and potential return to our investors We conduct calls with relevant Key Opinion Leaders for every opportunity to ensure we have the most informed and updated views from the leading voices in the field

Amgen Ventures has made >70 INVESTMENTS placing >$400M of the $625M Amgen has committed to support healthcare innovation and interconnectivity at all stages. Amgen Ventures offers us a unique conduit to identify and support key innovators in healthcare at early stages of translational sciences by providing investment capital and access to Amgen’s vast experience in developing leading drugs. AREAS OF INVESTMENTTHERAPEUTICS: Identify promising pipeline assets in Amgen’s therapeutic areas: oncology, immune- oncology, cardiovascular, inflammation, bone health, nephrology, metabolic disorders, and neuroscience. DRUG DISCOVERY & EMERGING TECHNOLOGIES: Improve the discovery process with new technologies including cell therapies, gene-editing and gene-therapies, regenerative medicine, and drug delivery. DIGITAL HEALTHCARE SERVICES, INFORMATION & ANALYTICS: Enhance Amgen medicines by improving real world outcomes and delivering greater value to healthcare systems, doctors, and patients.

Bioluminescence Ventures is a biotechnology venture firm investing in Drug Discovery Platforms (Oncology, Immunology, Neuroscience, Genetic Diseases), Applied Biology Platforms, and Computational Biology Platforms. The firm has AUM of $550M+ with offices in San Francisco and Cambridge (MA). Biomedical research is entering a Golden Age of Discovery – industrialized by HW/SW technologies, powered by longitudinal multi-modal data sets, and translated into novel therapies / therapeutic modalities by a new generation of multidisciplinary scientific founders. Bioluminescence was conceptualized and launched to potentiate this next generation of translational founders. Patient impact is our guiding light, and we see this light radiating from exceptional translational founders. Our growing team of multidisciplinary biotechnology researcher-operator-investors seek to earn trust through a shared understanding of the science and a shared vision for its potential to address unmet clinical needs. We seek to provide technical support as they translate and develop their science. We seek to provide financing support through the long and arduous journey. We also seek to provide business advisory and development support as the science matures toward co-development and co-commercialization partnerships. By obsessively and comprehensively meeting the needs of our founders, we aim to maximize their downstream impact on patients. We aim to make their light shine brighter.

We invest in early-stage opportunities that complement Takeda’s pipeline and products. Our mission is to create strategic growth opportunities for Takeda by investing and nurturing Innovative Life Science Companies in areas aligned with Takeda’s R&D focuses which include; Oncology, Gastroenterology, Neuroscience, and Rare Disease. Our aim is to access and support therapeutic and platform innovation working closely with academic innovators, entrepreneurs and investors. We invest in seeds or syndicated venture investing providing to the companies access to the resources of a multinational pharmaceutical company.